Abbott Laboratories filed a Form 8-K on November 16, 2026, disclosing that on November 11, 2026, it extended its Change-in-Control Agreements with named executive officers through December 31, 2028, while Chairman and CEO Robert B. Ford's agreement will expire on December 31, 2026.
Key Highlights
- Extension date: Abbott notified named executive officers on November 11, 2026, that their Agreements Regarding Change in Control were extended.
- New expiration: The extended agreements run through December 31, 2028, which is the second anniversary of the original Expiration Date of December 31, 2026.
- CEO excluded: Robert B. Ford, Abbott's Chairman of the Board and Chief Executive Officer, was not included in the extension; his agreement will expire on December 31, 2026.
- Signing officer: The filing was signed by Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer, dated November 13, 2026.
- Exchange listing: Abbott's common shares, without par value, trade under the symbol ABT on the NYSE:ABT and on the Chicago Stock Exchange, Inc.
Abbott's Change-in-Control Agreement Extensions and CEO Exception
According to the filing, Abbott Laboratories maintains Agreements Regarding Change in Control with its named executive officers. The filing notes that these agreements provide that if Abbott gives notification of extension before the Expiration Date of December 31, 2026, the agreement's term shall continue through the second anniversary of that date, which is December 31, 2028.
The company disclosed that on November 11, 2026, it notified the named executive officers, other than Robert B. Ford, Abbott's Chairman of the Board and Chief Executive Officer, that their agreements were extended through December 31, 2028. The filing states that Mr. Ford's Agreement will expire on December 31, 2026, with no extension reported for him.
The 8-K was filed under Item 5.02, covering departures, elections, appointments, and compensatory arrangements of certain officers. Abbott indicated that the agreements had been "as previously reported," referencing prior disclosure of these arrangements. The report was authorized and signed by Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer, with a signing date of November 13, 2026.
What Was Disclosed
Abbott Laboratories disclosed the extension of its Change-in-Control Agreements with named executive officers through December 31, 2028, while confirming that Chairman and CEO Robert B. Ford's agreement will not be extended and will expire on December 31, 2026.




Please wait processing your request...